Exelixis, Inc. 2000 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Exelixis, Inc.
Reporting Period: Fiscal year ended December 31, 2000
Business Model: Biotechnology company focused on discovering and validating novel drug targets for cancer and other diseases using comparative genomics and model system genetics. Revenue is derived primarily from strategic collaborations with pharmaceutical and agrochemical companies (e.g., Bayer, Pharmacia, Bristol-Myers Squibb, Dow AgroSciences, Aventis) rather than product sales.
Key Financial Metrics
| Metric (in thousands) | 2000 | 1999 |
|---|---|---|
| Total Revenues | $24,759 | $10,510 |
| Net Loss | $(75,311) | $(18,721) |
| Loss Per Share (Basic/Diluted) | $(2.43) | $(4.60) |
| Research & Development Expenses | $48,456 | $21,653 |
| Cash, Cash Equivalents & Short-Term Investments | $112,552 | $6,904 |
| Working Capital | $96,019 | $(672) |
| Accumulated Deficit | $(130,038) | $(54,727) |
Liquidity: The company holds approximately $112.6 million in cash and short-term investments as of December 31, 2000, bolstered by a $127.5 million net proceeds from its Initial Public Offering (IPO) in May 2000. Management believes current resources are sufficient for at least the next two years.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 135% to $24.8 million, driven by expanded collaborations with Bayer, Pharmacia, and Bristol-Myers Squibb, a new agreement with Dow AgroSciences, and the acquisition of Agritope.
- Acquisition of Agritope: In December 2000, Exelixis acquired Agritope, Inc. (renamed Exelixis Plant Sciences) for approximately $93.5 million in stock and transaction costs. This resulted in a one-time non-cash charge of $38.1 million for acquired in-process research and development (IPR&D).
- Expense Surge: Operating expenses rose to $105.7 million from $29.3 million. This includes the $38.1 million IPR&D charge, increased R&D spending ($48.5 million), and higher general and administrative costs ($18.9 million) due to public company compliance and facility expansion.
- Stock Compensation: Amortization of deferred stock compensation increased significantly to $14.0 million in 2000 compared to $3.5 million in 1999.
Guidance, Outlook, and Risks
Outlook: Exelixis expects to continue incurring net losses and negative cash flow for the foreseeable future as it expands R&D and internal development programs. The company anticipates operating expenses will increase significantly in the near term.
Key Risks and Contingencies:
- Dependence on Collaborators: Substantially all revenues are derived from collaborations. Bayer and Pharmacia accounted for approximately 53% and 36% of 2000 revenues, respectively. Termination of these agreements would have a material adverse effect.
- Pharmacia Restructuring: Pharmacia is restructuring operations into a new European enterprise. Exelixis is negotiating an amendment to assign research work and funding to this new entity, but there is no assurance funding will be maintained beyond Q1 2002.
- Capital Requirements: Future capital needs are substantial. If additional funding is required, it may be dilutive to shareholders or involve restrictive covenants.
- Regulatory and IP Risks: The company faces risks related to the lengthy regulatory approval process for future products and potential intellectual property infringement claims.
Investor Verification Checklist
- Collaboration Renewals: Verify the status of negotiations regarding the Pharmacia restructuring and the continuation of funding commitments.
- Cash Burn Rate: Monitor quarterly cash flow to ensure the $112.6 million cash balance supports the projected two-year runway given increasing R&D expenses.
- Acquisition Integration: Assess the progress of integrating Agritope's agricultural genomics platform and the commercial viability of its in-process projects.
- Stock Option Dilution: Review the impact of the large stock option grants (weighted average exercise price of $17.70) on future earnings per share and equity dilution.
- Revenue Concentration: Evaluate the risk exposure associated with the heavy reliance on Bayer and Pharmacia for over 89% of total revenue.